Brief: Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III Maveric Trial In Recurrent Pericarditis
16/04/2025 13:20
April 16 (Reuters) - Cardiol Therapeutics Inc CRDL.TO: CARDIOL THERAPEUTICS ENROLLS FIRST PATIENT IN PIVOTAL PHASE III MAVERIC TRIAL IN RECURRENT PERICARDITIS Source text: [ID:n0001062993-25-007566] Further company coverage: CRDL.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:11 AM
Brief: Cardiol Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III Maveric Trial In Recurrent Pericarditis